T
ThinkingSapien
Guest
Drug maker AstraZeneca has announced that it is pausing it’s COVID-19 vaccine trial due to a “potentially unexplained illness” in one of the trial volunteers.
The vaccine was developed by the University of Oxford in partnership with Astra Zeneca. It’s being studied in thousands of patients in the United States and the United Kingdom. The illness apparently occurred in a U.K. volunteer.
The company hasn’t revealed the nature of the illness, but did confirm that a pause in vaccination will allow a safety review. “This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials,” an AstraZeneca spokesperson said in a statement to NPR.
The next step will be to determine if the illness is indeed related to the vaccine, or just a chance event.
The AstraZeneca/Oxford partnership is one of the vaccine development efforts that is furthest along. The company recently began a Phase 3 trial in the United States that aims to enroll 30,000 volunteers.
The vaccine is what’s known as a non-replicating viral vector vaccine. When injected into a volunteer, it tricks that person’s cells into making a protein from SARS-CoV-2, the virus that causes COVID-19. That has the effect of prompting the vaccinated person to have an immune reaction that should be protective if the person were exposed to the coronavirus.